Table 3.

Pooled HBV reactivation rates in inflammatory arthritis patients with chronic HBV infection, with or without antiviral prophylaxis

Chronic* HBV	Antiviral prophylaxis (+)				Antiviral prophylaxis (−)
	N	Event	Pooled Rate,% (95%CI)	P value**	N	Event	Pooled Rate,% (95%CI)	P value**
Summary***	99	10	9.0 (4.1–15.5)	0.02	160	24	14.6 (4.3–29.0)	<0.001
TNF-alpha inhibitors	57	2	4.4 (0.4–11.7)	0.73	64	11	15.6 (2.3–35.7)	0.05
Non-biologic DMARDs	29	8	27.1 (12.4–44.8)	0.09	58	13	22.4 (8.1–40.8)	0.11

^*Chronic HBV: HbsAg (+);

^**P value for study heterogeneity within drug classes. TNF: tumor necrosis factor

^***Numbers do not add-up because there was only one study for chronic HBV infection patients receiving non-TNF biologic DMARDs (17) without (N=38) and with (N=13) antivirals, which was not eligible for subgroup analyses. No reactivation was observed in this study.